克莱姆生物

最新新闻

• 评级变动
  Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG)
  TipRanks · 2026/6/15
• 评级变动
  Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $24
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• 评级变动
  RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• B. Riley Securities Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• 评级变动
  Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/25
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI) and Climb Bio (CLYM)
  TipRanks · 2026/7/14
• 评级变动
  Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 评级变动
  RBC Capital Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/6/24
• BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  William Blair Maintains Climb Bio(CLYM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/19

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。